Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.46 |
| ▸ | TP53 | P04637 | 2/20 | 0.45 |
| ▸ | NAMPT | P43490 | 4/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.41 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.41 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.41 |
| ▸ | PTAFR | P25105 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26295479 | 0.84 | P2RX7 (0.41) | P2RX7TP53NAMPTKMT2AKDM4E | |
| SCHEMBL26295471 | 0.84 | ACVR1B (0.46) | P2RX7TP53KMT2AKDM4EMEN1 | |
| SCHEMBL26295453 | 0.84 | ACVR1B (0.46) | P2RX7TP53KMT2AKDM4EMEN1 | |
| SCHEMBL23950565 | 0.82 | ALDH1A1 (0.47) | HTTKDM4E | |
| SCHEMBL30101935 | 0.82 | ALDH1A1 (0.47) | HTTKDM4E | |
| SCHEMBL25403249 | 0.81 | AHR (0.44) | P2RX7TP53KMT2AKDM4EMEN1 | |
| SCHEMBL23950751 | 0.81 | MKNK1 (0.56) | KMT2A | |
| SCHEMBL23390484 | 0.79 | MAPK1 (0.52) | TP53KMT2AKDM4EMEN1 | |
| SCHEMBL30101922 | 0.79 | MAPK1 (0.52) | TP53KMT2AKDM4EMEN1 | |
| SCHEMBL26295468 | 0.79 | MKNK1 (0.41) | TP53KMT2AHTTKDM4EMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | SENDA BIOSCIENCES, INC. (US) | 2023-09-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295152-A1 | PYRIDOPYRIMIDINONE DERIVATIVES AS AHR ANTAGONISTS | AHR, ARNT, AIPL1 | P2RX7 174/4885TP53 311/4885NAMPT 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.